Group 1 - The core viewpoint of the news is that Huaxia Fund is launching two ETFs, the Huaxia CSI 300 ETF and the Huaxia Sci-Tech 50 ETF, in Thailand through depositary receipts (DR), marking a significant step in the internationalization of Chinese assets and deepening cooperation between China and Thailand under the Belt and Road Initiative [1][2]. - The launch of the Huaxia Sci-Tech 50 ETF DR highlights China's strength in "hard technology," focusing on leading companies in strategic emerging industries such as semiconductors and biomedicine, filling a gap in Southeast Asia for investments in China's hard tech sector [2]. - The simultaneous listing of both ETFs provides a dual-driven strategy of "core assets + hard tech," offering international investors a direct channel to invest in high-quality Chinese assets and share in the benefits of China's technological transformation [2][3]. Group 2 - Huaxia Fund is recognized as a pioneer in the internationalization of Chinese asset management, leveraging its strong index investment management capabilities and extensive cross-border business experience [3]. - The project utilizes an innovative cross-border ecosystem, where Thailand's InnovestX Securities purchases the underlying ETFs through the "Northbound Trading" mechanism in Hong Kong and issues DRs in Thailand, enhancing connectivity between the Chinese, Hong Kong, and Thai markets [3]. - Thai investors can trade in local currency without needing to open overseas accounts, benefiting from tax exemptions on capital gains, which significantly enhances the convenience of cross-border investments and showcases a new level of openness in China's capital market [3].

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 100 Index decreased by 0.46% as of July 18, 2025, with mixed performance among constituent stocks [1] - BoRui Pharmaceutical led the gains with an increase of 6.37%, while Yuanjie Technology experienced the largest decline at 4.94% [1] - The Huaxia Sci-Tech 100 ETF (588800) fell by 0.49%, with a latest price of 1.01 yuan and a turnover rate of 5.36%, amounting to a transaction volume of 158 million yuan [1] Group 2 - CITIC Securities highlights that despite increasing external challenges, the competitiveness of China's pharmaceutical industry continues to rise, with innovative drugs gaining international recognition [2] - China possesses advantages in population and domestic demand, manufacturing and supply chain, while its innovation capabilities are rapidly improving [2] - The Huaxia Sci-Tech 100 ETF (588800) shows that stocks with a market capitalization below 20 billion yuan account for 80% of its holdings, indicating a focus on small-cap stocks [2]